Literature DB >> 20204428

Hydroxyurea as an inhibitor of hepatitis C virus RNA replication.

Akito Nozaki1, Manabu Morimoto, Masaaki Kondo, Takashi Oshima, Kazushi Numata, Shin Fujisawa, Takeshi Kaneko, Eiji Miyajima, Satoshi Morita, Kyoko Mori, Masanori Ikeda, Nobuyuki Kato, Katsuaki Tanaka.   

Abstract

Hepatitis C virus (HCV) is the main causative agent of chronic liver disease, which may develop into liver cirrhosis and hepatocellular carcinoma. By using a recently developed reporter assay system in which genome-length HCV RNA replicates efficiently, we found that hydroxyurea (HU), a DNA synthesis inhibitor, inhibited HCV RNA replication. Moreover, we demonstrated that the anti-HCV activity of the combination of IFN-alpha and HU was higher than that of IFN-alpha alone. These results suggest that HU may be an effective anti-HCV reagent that can be used not only singly but also in combination with IFN-alpha to treat chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20204428     DOI: 10.1007/s00705-010-0624-1

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  6 in total

1.  Development of a drug assay system with hepatitis C virus genome derived from a patient with acute hepatitis C.

Authors:  Kyoko Mori; Youki Ueda; Yasuo Ariumi; Hiromichi Dansako; Masanori Ikeda; Nobuyuki Kato
Journal:  Virus Genes       Date:  2012-01-18       Impact factor: 2.332

2.  Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine.

Authors:  Christine L Clouser; Colleen M Holtz; Mary Mullett; Duane L Crankshaw; Jacquie E Briggs; Jay Chauhan; Ilze Matise VanHoutan; Steven E Patterson; Louis M Mansky
Journal:  PLoS One       Date:  2011-01-14       Impact factor: 3.240

3.  New preclinical antimalarial drugs potently inhibit hepatitis C virus genotype 1b RNA replication.

Authors:  Youki Ueda; Midori Takeda; Kyoko Mori; Hiromichi Dansako; Takaji Wakita; Hye-Sook Kim; Akira Sato; Yusuke Wataya; Masanori Ikeda; Nobuyuki Kato
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

4.  Peg-interfon alpha-2a and low-dose ribavirin for treatment of hepatitis C virus infection in patients with sickle-cell anemia in Saudi Arabia.

Authors:  Adnan Agha; Rafaat Chakik; Mamdouh M Abdulhadi Ali; Dib Alsaudi; Giorgio Sammito; Edoardo Giovanni Giannini
Journal:  Ann Saudi Med       Date:  2013 Nov-Dec       Impact factor: 1.526

5.  Widespread Natural Occurrence of Hydroxyurea in Animals.

Authors:  David I Fraser; Kyle T Liu; Bryan J Reid; Emily Hawkins; Andrew Sevier; Michelle Pyle; Jacob W Robinson; Pierre H R Ouellette; James S Ballantyne
Journal:  PLoS One       Date:  2015-11-24       Impact factor: 3.240

6.  Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review.

Authors:  Y C Tsai; T F Tsai
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-09-03       Impact factor: 5.346

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.